LAVA Therapeutics (NASDAQ:LVTX) Cut to “Hold” at Leerink Partnrs

LAVA Therapeutics (NASDAQ:LVTX) was downgraded by investment analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Other analysts also recently issued research reports about the company. Leerink Partners restated a “market perform” rating and set a $2.00 target price (down previously from $11.00) on shares of LAVA Therapeutics in a research note on Thursday. Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Finally, JMP Securities restated a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $4.67.

LAVA Therapeutics Trading Down 0.8 %

Shares of NASDAQ:LVTX opened at $1.20 on Thursday. LAVA Therapeutics has a 1 year low of $1.15 and a 1 year high of $6.47. The business has a fifty day simple moving average of $1.70 and a 200 day simple moving average of $1.84.

Hedge Funds Weigh In On LAVA Therapeutics

Institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in shares of LAVA Therapeutics during the third quarter valued at approximately $32,000. XTX Topco Ltd bought a new stake in LAVA Therapeutics in the second quarter worth about $55,000. Finally, Pathway Financial Advisors LLC lifted its stake in LAVA Therapeutics by 328.6% in the second quarter. Pathway Financial Advisors LLC now owns 60,000 shares of the company’s stock valued at $108,000 after purchasing an additional 46,000 shares during the last quarter.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.